AR117570A1 - Composición farmacéutica para suprimir la fibrilación auricular con anticuerpo anti-ngf humano o fragmento de unión al antígeno del mismo ingrediente activo - Google Patents

Composición farmacéutica para suprimir la fibrilación auricular con anticuerpo anti-ngf humano o fragmento de unión al antígeno del mismo ingrediente activo

Info

Publication number
AR117570A1
AR117570A1 ARP190101302A ARP190101302A AR117570A1 AR 117570 A1 AR117570 A1 AR 117570A1 AR P190101302 A ARP190101302 A AR P190101302A AR P190101302 A ARP190101302 A AR P190101302A AR 117570 A1 AR117570 A1 AR 117570A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
active ingredient
binding fragment
atrial fibrillation
antigen binding
Prior art date
Application number
ARP190101302A
Other languages
English (en)
Inventor
Toshiaki Aoki
Kohsuke Shakushiro
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of AR117570A1 publication Critical patent/AR117570A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se provee una composición farmacéutica para suprimir la fibrilación auricular, que tiene un mecanismo de acción que no afecta la función normal del corazón. Se provee una composición farmacéutica que incluye un anticuerpo anti-NGF humano o un fragmento de unión al antígeno del mismo, como ingrediente activo.
ARP190101302A 2018-05-15 2019-05-15 Composición farmacéutica para suprimir la fibrilación auricular con anticuerpo anti-ngf humano o fragmento de unión al antígeno del mismo ingrediente activo AR117570A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018093616 2018-05-15

Publications (1)

Publication Number Publication Date
AR117570A1 true AR117570A1 (es) 2021-08-18

Family

ID=68540223

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101302A AR117570A1 (es) 2018-05-15 2019-05-15 Composición farmacéutica para suprimir la fibrilación auricular con anticuerpo anti-ngf humano o fragmento de unión al antígeno del mismo ingrediente activo

Country Status (6)

Country Link
US (1) US20210147529A1 (es)
EP (1) EP3795176A4 (es)
JP (1) JPWO2019221097A1 (es)
AR (1) AR117570A1 (es)
TW (1) TW202003039A (es)
WO (1) WO2019221097A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111297474B (zh) * 2019-12-19 2022-11-08 成都迈格因科技有限公司 心房颤动病灶的个体化定位标测系统

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527358A (en) * 1994-01-21 1996-06-18 Medtronic, Inc. Temporary medical electrical lead
CA2500901A1 (en) * 2002-10-04 2004-04-22 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
PT2270048E (pt) 2002-12-24 2016-02-10 Rinat Neuroscience Corp Anticorpos anti-ngf e métodos de utilização dos mesmos
EA013614B1 (ru) 2003-07-15 2010-06-30 Амджен Инк. Изолированное антитело к фактору роста нервов (ngf) и способы его применения
CA2595800C (en) 2005-01-24 2014-07-08 Cambridge Antibody Technology Limited. Specific binding members for ngf
JP2007244601A (ja) * 2006-03-15 2007-09-27 Kanazawa Univ 心筋用パッド
CA2695997C (en) 2007-08-10 2016-11-22 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
PL2448970T3 (pl) 2009-05-04 2014-12-31 Abbvie Res B V Przeciwciało przeciwko czynnikowi wzrostu nerwów (NGF) ze zwiększoną stabilnością in vivo
EP2654714B1 (en) * 2010-12-20 2018-07-25 Cormatrix Cardiovascular, Inc. A drug eluting patch for the treatment of localized tissue disease or defect
CA2841181C (en) 2011-08-11 2022-01-25 Astellas Pharma Inc. Anti-human ngf antibody
CN107614683B (zh) 2015-05-22 2020-12-22 安斯泰来制药株式会社 新型抗人NGF抗体Fab片段

Also Published As

Publication number Publication date
TW202003039A (zh) 2020-01-16
JPWO2019221097A1 (ja) 2021-05-27
EP3795176A4 (en) 2022-01-12
EP3795176A1 (en) 2021-03-24
US20210147529A1 (en) 2021-05-20
WO2019221097A1 (ja) 2019-11-21

Similar Documents

Publication Publication Date Title
MX2020004948A (es) Receptor de antígeno quimérico que selecciona como diana bcma, receptor de antígeno quimérico que selecciona como diana cd19 y terapias de combinación.
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
EA201892480A1 (ru) Соединения, модулирующие fxr (nr1h4)
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
EA202190485A1 (ru) Соединения, модулирующие fxr (nr1h4)
BR112016013187A2 (pt) receptores de antígenos quiméricos de mesotelina humanos e usos dos mesmos
CR20170600A (es) Anticuerpos del factor x1 y métodos de uso
CO2018001473A2 (es) Anticuerpos inhibidores de vía del factor tisular y usos de los mismos
BR112021007902A2 (pt) Anticorpo anti-cd73, fragmento de ligação ao antigênio e aplicação dos mesmos
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
EA201990548A1 (ru) Лечение кластерной головной боли
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
CO2019007823A2 (es) Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo
BR112017006520A2 (pt) métodos de tratamento do lúpus eritematoso sistêmico usando um anticorpo de domínio direcionado contra cd28
BR112017020413A2 (pt) ?anticorpo anti-notch4 humano?
BR112016002401A2 (pt) métodos para reduzir as taxas de exacerbação de asma usando benralizumab
EA201591397A1 (ru) Хиноксалиноны и дигидрохиноксалиноны как антивирусные средства против респираторно-синцитиального вируса
ECSP19026593A (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
BR112018073945A2 (pt) métodos para tratamento de miastenia grave generalizada refratária
CO2017000412A2 (es) Composiciones parasiticidas que comprenden derivados de indol
BR112018015090A2 (pt) anticorpo anti-trombina, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos
CL2021003326A1 (es) Anticuerpo anti-epha4 humano.
BR112018072263A2 (pt) métodos de tratamento de doenças nas quais atividade de il-13 é prejudicial usando anti-anticorpos anti-il-13

Legal Events

Date Code Title Description
FB Suspension of granting procedure